南华生物医药股份有限公司 关于债权转让暨关联交易的进展公告

Group 1 - The company has approved a debt transfer and related party transaction, allowing the transfer of certain accounts receivable to Hunan Caixin Asset Management Co., Ltd. for a consideration of no less than 23.4144 million yuan [1] - As of the announcement date, the company's wholly-owned subsidiary, Nanhua Stem Cell Regenerative Medicine Clinical Transformation Research Center Co., Ltd., has received the debt transfer payment of 23.4144 million yuan from Caixin Asset [2] - The relevant documents for this transaction include the Debt Transfer Agreement and the Bank Electronic Receipt [3]